Merck, Inc.
🇺🇸United States
Efficacy and Tolerability Study of V501 in Japanese Males (V501-122)
Phase 3
Completed
- Conditions
- Condyloma AcuminataAnogenital Human Papilloma Virus Infection
- Interventions
- Biological: PlaceboBiological: V501
- First Posted Date
- 2013-05-27
- Last Posted Date
- 2019-04-02
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 1124
- Registration Number
- NCT01862874
A Study of the Safety and Efficacy of Anacetrapib (MK-0859) Among Participants With Hypercholesterolemia When Added to Ongoing Statin Therapy (MK-0859-022)
- First Posted Date
- 2013-05-23
- Last Posted Date
- 2020-05-29
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 589
- Registration Number
- NCT01860729
MK-8237 (SCH900237) Biomarker Study in Participants With Allergic Rhinitis or Rhinoconjunctivitis (MK-8237-009)
Phase 1
Completed
- Conditions
- Allergic RhinoconjunctivitisAllergic Rhinitis
- Interventions
- Biological: MK-8237Biological: NACOther: Placebo
- First Posted Date
- 2013-05-14
- Last Posted Date
- 2019-03-15
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 26
- Registration Number
- NCT01852825
Samatasvir (IDX719) in Combinations With Simeprevir and/or TMC647055/Ritonavir With or Without Ribavirin for 12 Weeks in Participants With Chronic Hepatitis C Infection (MK-1894-005)
Phase 2
Completed
- Conditions
- Chronic Hepatitis C Virus
- Interventions
- Biological: Pegylated interferon (Peg-IFN)Other: Samatasvir matching placebo
- First Posted Date
- 2013-05-14
- Last Posted Date
- 2015-04-23
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 143
- Registration Number
- NCT01852604
Efficacy and Safety of MK-7622 as Adjunct Therapy in Participants With Alzheimer's Disease (MK-7622-012)
- First Posted Date
- 2013-05-13
- Last Posted Date
- 2018-09-18
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 240
- Registration Number
- NCT01852110
Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-012/KEYNOTE-012)
Phase 1
Completed
- Conditions
- CancerSolid Tumor
- Interventions
- Biological: Pembrolizumab
- First Posted Date
- 2013-05-08
- Last Posted Date
- 2021-06-28
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 297
- Registration Number
- NCT01848834
Study to Evaluate the Safety and Efficacy of the Addition of Omarigliptin (MK-3102) Compared With the Addition of Sitagliptin in Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin (MK-3102-026)
Phase 3
Completed
- Conditions
- Type 2 Diabetes
- Interventions
- First Posted Date
- 2013-04-26
- Last Posted Date
- 2018-09-10
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 642
- Registration Number
- NCT01841697
Efficacy and Tolerability of Anacetrapib Added to Ongoing Lipid-Lowering Therapy in Adult Participants With Homozygous Familial Hypercholesterolemia (HoFH) (MK-0859-042)
Phase 3
Terminated
- Conditions
- Homozygous Familial HypercholesterolemiaHyperlipoproteinemia Type II
- Interventions
- Drug: Placebo
- First Posted Date
- 2013-04-26
- Last Posted Date
- 2015-06-01
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 2
- Registration Number
- NCT01841684
Study of Pembrolizumab (MK-3475) Monotherapy in Advanced Solid Tumors and Pembrolizumab Combination Therapy in Advanced Non-small Cell Lung Cancer/ Extensive-disease Small Cell Lung Cancer (MK-3475-011/KEYNOTE-011)
Phase 1
Completed
- Conditions
- Solid TumorNon-small Cell Lung CancerSmall Cell Lung Cancer
- Interventions
- Biological: Pembrolizumab 2 mg/kgBiological: Pembrolizumab 10 mg/kgBiological: Pembrolizumab 200 mgBiological: Ipilimumab 1 mg/kgDrug: Nab-paclitaxel 100 mg/m^2
- First Posted Date
- 2013-04-25
- Last Posted Date
- 2021-06-22
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 57
- Registration Number
- NCT01840579
The Pharmacokinetics of MK-7145 Following Single Dose Administration in Participants With Moderate Renal Insufficiency (MK-7145-018)
- First Posted Date
- 2013-04-15
- Last Posted Date
- 2013-09-24
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Registration Number
- NCT01832103